Analysis of the effects of mEHT on the treatment-related toxicity and quality of life of HIV-positive cervical cancer patients

References

• Hillemanns P, Soergel P, Hertel H, et al. Epidemiology and early detection of cervical cancer. Oncol Res Treat. 2016;39(9):501–506.
   PubMed Web of Science ®Google Scholar
• Goodman A. HPV testing as a screen for cervical cancer. BMJ. 2015;350(1):H2372.
   PubMed Web of Science ®Google Scholar
• Oliver NT, Chiao EY. Malignancies in women with HIV infection. Curr Opin HIV AIDS. 2017;12(1):69–76.
   PubMed Web of Science ®Google Scholar
• Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl 4): 72–83.
   Web of Science ®Google Scholar
• Lutgens L, Koper PCM, Jobsen JJ, et al. Radiation therapy combined with hyperthermia versus cisplatin for locally advanced cervical cancer: results of the randomized RADCHOC trial. Radiother Oncol. 2016;120(3):378–382.
   PubMed Web of Science ®Google Scholar
• Lutgens L, Van Der Zee J, Pijls-Johannesma M, et al. Combined use of hyperthermia and radiation therapy for treating locally advanced cervical carcinoma. Cochrane Database Syst Rev. 2010;1:CD006377.
   PubMedGoogle Scholar
• Datta NR, Rogers S, Klingbiel D, et al. Hyperthermia and radiotherapy with or without chemotherapy in locally advanced cervical cancer: a systematic review with conventional and network meta-analyses. Int J Hyperth. 2016;32(7):809–821.
   PubMed Web of Science ®Google Scholar
• Franckena M, Stalpers LJA, Koper PCM, et al. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch deep hyperthermia trial. Int J Radiat Oncol Biol Phys. 2008;70(4):1176–1182.
   PubMed Web of Science ®Google Scholar
• Harima Y, Nagata K, Harima K, et al. A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma. Int J Hyperth. 2009;25(5):338–343.
   PubMed Web of Science ®Google Scholar
• van der Zee J, González González D. The Dutch deep hyperthermia trial: results in cervical cancer. Int J Hyperth. 2002;18(1):1–12.
   PubMed Web of Science ®Google Scholar
• Franckena M, de Wit R, Ansink AC, et al. Weekly systemic cisplatin plus locoregional hyperthermia: an effective treatment for patients with recurrent cervical carcinoma in a previously irradiated area. Int J Hyperth. 2007;23(5):443–450.
   PubMed Web of Science ®Google Scholar
• Rietbroek RC, Bakker PJM, Schilthuis MS, et al. Feasibility, toxicity, and preliminary results of weekly loco-regional hyperthermia and cisplatin in patients with previously irradiated recurrent cervical carcinoma or locally advanced bladder cancer. Int J Radiat Oncol Biol Phys. 1996;34(4):887–893.
   PubMed Web of Science ®Google Scholar
• Westermann AM, Jones EL, Schem B, et al. First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma. Cancer. 2005;104(4):763–770.
   PubMed Web of Science ®Google Scholar
• Sreenivasa G, Hildebrandt B, Kummel S, et al. Radiochemotherapy combined with regional pelvic hyperthermia induces high response and resectability rates in patients with nonresectable cervical cancer > or = FIGO IIB “bulky. Int J Radiat Oncol Biol Phys. 2006;66(4):1159–1167.
   PubMed Web of Science ®Google Scholar
• Bergs JWJ, Franken NAP, Haveman J, et al. Hyperthermia, cisplatin and radiation trimodality treatment: a promising cancer treatment? A review from preclinical studies to clinical application. Int J Hyperth. 2007;23(4):329–341.
   PubMed Web of Science ®Google Scholar
• Franckena M, Fatehi D, De BM, et al. Hyperthermia dose-effect relationship in 420 patients with cervical cancer treated with combined radiotherapy and hyperthermia. Eur J Cancer. 2009;45(11):1969–1978.
   PubMed Web of Science ®Google Scholar
• Wielheesen DHM, Smitt P, Haveman J, et al. Incidence of acute peripheral neurotoxicity after deep regional hyperthermia of the pelvis. Int J Hyperth. 2009;672436(4):367–375.
   Web of Science ®Google Scholar
• Gichangi P, Bwayo J, Estambale B, et al. HIV impact on acute morbidity and pelvic tumor control following radiotherapy for cervical cancer. Gynecol Oncol. 2006;100(2):405–411.
   PubMed Web of Science ®Google Scholar
• Simonds HM, Neugut AI, Jacobson JS. HIV Status and acute hematological toxicity among cervix cancer patients undergoing radical chemoradiation. Int J Gynecol Cancer. 2015;25(5):884–890.
   PubMed Web of Science ®Google Scholar
• Herd O, Francies F, Kotzen J, et al. Chromosomal radiosensitivity of human immunodeficiency virus positive/negative cervical cancer patients in South Africa. Mol Med Rep. 2016;13(1):130–136.
   PubMed Web of Science ®Google Scholar
• Baeyens A, Slabbert JP, Willem P, et al. Chromosomal radiosensitivity of HIV positive individuals. Int J Radiat Biol. 2010;86(7):584–592.
   PubMed Web of Science ®Google Scholar
• Formenti SC, Chak L, Gill P, et al. Increased radiosensitivity of normal tissue fibroblasts in patients with acquired immunodeficiency syndrome (AIDS) and with kaposi’s sarcoma. Int J Radiat Biol. 1995;68(4):411–412.
   PubMed Web of Science ®Google Scholar
• Nisce LZ, Safai B. Radiation therapy of Kaposi’s sarcoma in AIDS: Memorial Sloan-Kettering experience. New York (NY): S Karger Publishers Inc; 1985.
   Google Scholar
• Housri N, Yarchoan R, Kaushal A. Radiotherapy for HIV patients: are special precautions necessary? Cancer. 2010;116(2):273–283.
   PubMed Web of Science ®Google Scholar
• Vallis KA. Glutathione deficiency and radiosensitivity in AIDS patients. Lancet. 1991;337(8746):918–919.
   PubMed Web of Science ®Google Scholar
• Fiorentini G, Szasz A. Hyperthermia today: electric energy, a new opportunity in cancer treatment. J Can Res Ther. 2006;2(2):41–46.
   PubMedGoogle Scholar
• Szasz O, Szigeti GP, Szasz A. Connections between the specific absorption rate and the local temperature. Open J Biophys. 2016;06 (03):53–74.
   Google Scholar
• Szigeti GP, Szasz O, Hegyi G. Personalised dosing of hyperthermia. J Cancer Diagn. 2016;01 (02):1–9.
   Google Scholar
• Szasz O, Andocs G, Meggyeshazi N. Modulation effect in oncothermia. Conf Pap Med. 2013;2013:1–5.
   Google Scholar
• Vincze G, Szasz A. Similarities of modulation by temperature and by electric field. Open J Biophys. 2018;08 (03):95–103.
   Google Scholar
• Yang K, Huang C, Chi M, et al. In vitro comparison of conventional hyperthermia and modulated. Oncotarget. 2016;7(51):84082–84092.
   PubMedGoogle Scholar
• Andocs G, Renner H, Balogh L, et al. Strong synergy of heat and modulated electromagnetic field in tumor cell killing. Strahlenther Onkol. 2009;185(2):120–126.
   PubMed Web of Science ®Google Scholar
• Lee S-Y, Kim J-H, Han Y-H, et al. The effect of modulated electro-hyperthermia on temperature and blood flow in human cervical carcinoma. Int J Hyperth. 2018;34(7):953–960.
   PubMed Web of Science ®Google Scholar
• Lee S, Lee N, Cho D, et al. Treatment outcome analysis of chemotherapy combined with modulated electro-hyperthermia compared with chemotherapy alone for recurrent cervical cancer, following irradiation. Oncol Lett. 2017;14(1):73–78.
   PubMed Web of Science ®Google Scholar
• Minnaar CA, Kotzen JA, Ayeni AO, et al. The effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: early results from a phase III randomised controlled trial. PLoS One. 2019;14(6):e0217894.
   PubMed Web of Science ®Google Scholar
• Minnaar C, Baeyens A, Kotzen J, et al. Survival of cervical cancer patients with or without associated HIV infection and treated with modulated electrohyperthermia combined with chemo-radiotherapy. Strahlentherapie Und Onkol. 2018;194(5):476.
   Web of Science ®Google Scholar
• Chase DM, Huang HQ, Wenzel L, et al. Quality of life and survival in advanced cervical cancer: a gynecologic oncology group study. Gynecol Oncol. 2012;125(2):315–319.
   PubMed Web of Science ®Google Scholar
• van der Zee J, Vujaskovic Z, Kindo M, et al. The Kadota Fund International Forum 2004—clinical group consensus. Int J Hyperth. 2008;24(2):111–112.
   PubMed Web of Science ®Google Scholar
• Sapozink MD, Corry PM, Kapp DS, et al. RTOG quality assurance guidelines for clinical trials using hyperthermia for deep-seated malignancy. Int J Radiat Oncol Biol Phys. 1991;20(5):1109–1115.
   PubMed Web of Science ®Google Scholar
• van Rhoon GC. Is CEM43 still a relevant thermal dose parameter for hyperthermia treatment monitoring? Int J Hyperth. 2016;6736:1–13.
   Google Scholar
• Szasz O, Szigeti GP, Vancsik T, et al. Hyperthermia dosing and depth of effect. Open J Biophys. 2018;08 (1):31–48.
   Google Scholar
• Paken J, Govender CD, Pillay M, et al. Cisplatin-associated ototoxicity: a review for the health professional. J Toxicol. 2016;2016:1–13.
   Web of Science ®Google Scholar
• Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci Lett. 2015;596:90–107.
   PubMed Web of Science ®Google Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmac. 2014;740:364–378.
   PubMed Web of Science ®Google Scholar
• Koller M, Aaronson NK, Blazeby J, et al. Translation procedures for standardised quality of life questionnaires: the European Organisation for Research and Treatment of Cancer (EORTC) approach. Eur J Cancer. 2007;43(12):1810–1820.
   PubMed Web of Science ®Google Scholar
• Fayers P, Bottomley A. Quality of life research within the EORTC—the EORTC QLQ-C30. Eur J Cancer. 2002;38(4):125–133.
   Google Scholar
• Aaronson N, Ahmedzai S, Bergman B, et al. The European organisation for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376.
   PubMed Web of Science ®Google Scholar
• Fayers P, Aaronson N, Bjordal K, et al. The EORTC QLQ-C30 scoring manual. 3rd ed. Brussels Belgium: European Organisation for Research and Treatment of Cancer; 2001.
   Google Scholar
• The American Cancer Society medical and editorial content team. Normal weight ranges: body mass index (BMI) [Internet]. 2015 [cited 2019 Jan 2]. Available from: https://www.cancer.org/cancer/cancer-causes/diet-physical-activity/body-weight-and-cancer-risk/adult-bmi.html
   Google Scholar
• Kok HP, Crezee J. A comparison of the heating characteristics of capacitive and radiative superficial hyperthermia. Int J Hyperth. 2017;33(4):378–386.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio V, Dughiero F. Numerical model for RF capacitive regional deep hyperthermia in pelvic tumors. Med Bio Eng Comput. 2007;45(5):459–466.
   PubMed Web of Science ®Google Scholar
• Kim W, Kim M, Kim H, et al. Role of HIF-1 α in response of tumors to a combination of hyperthermia and radiation in vivo. Int J Hyperth. 2018;34(3):276–283.
   PubMed Web of Science ®Google Scholar
• Yang W, Han GH, Shin H, et al. Combined treatment with modulated electro- hyperthermia and an autophagy inhibitor effectively inhibit ovarian and cervical cancer growth. Int J Hyperth. 2019;36(1):9–20.
   PubMed Web of Science ®Google Scholar
• Wust P, Ghadjar P, Nadobny J, et al. Physical analysis of temperature-dependent effects of amplitude- modulated electromagnetic hyperthermia. Int J Hyperth. 2019;36(1):1245–1253.
   Web of Science ®Google Scholar
• Poglio S, Galvani S, Bour S. Adipose tissue sensitivity to radiation exposure. Am J Pathol. 2009;174(1):44–53.
   PubMed Web of Science ®Google Scholar
• Shukla L, Morrison WA, Shayan R. Adipose-derived stem cells in radiotherapy injury: a new frontier. Front Surg. 2015;2:10–13.
   PubMed Web of Science ®Google Scholar
• Franckena M, Lutgens LC, Koper PC, et al. Radiotherapy and hyperthermia for treatment of primary locally advanced cervix cancer: results in 378 patients. Int J Radiat Oncol Biol Phys. 2009;73(1):242–250.
   PubMed Web of Science ®Google Scholar
• Vendrell I, Ferreira AR, Abrunhosa-Branquinho AN, et al. Chemoradiotherapy completion and neutropenia risk in HIV patients with cervical cancer. Medicine. 2018;97(30):e11592.
   PubMed Web of Science ®Google Scholar
• Levinson KL, Riedel DJ, Ojalvo LS, et al. Gynecologic cancer in HIV-infected women: treatment and outcomes in a multi-institutional cohort. Aids. 2018;32(2):171–177.
   PubMed Web of Science ®Google Scholar
• Mdletshe S, Munkupa H, Lishimpi K. Acute toxicity in cervical cancer HIV-positive vs. HIV-negative patients treated by radical chemo-radiation in Zambia. South African J Gynaecol Oncol. 2016;8(2):37–41.
   Web of Science ®Google Scholar
• Triantopoulou S, Platoni K, Antypas C, et al. Quality assurance protocol for superficial and deep hyperthermia systems established by the Hellenic Association of Medical Physicists (HAMP) in cooperation with the Hellenic Society of Oncologic Hyperthermia (HSOH): a study based on European Society. J Balkon Union Oncol. 2018;23(2):494–499.
   PubMed Web of Science ®Google Scholar
• Bruggmoser G, Bauchowitz S, Canters R, et al. Quality assurance for clinical studies in regional deep hyperthermia. Strahlenther Onkol. 2011;187(10):605–610.
   PubMed Web of Science ®Google Scholar